BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Blumhardt R, Wolin EA, Phillips WT, Salman UA, Walker RC, Stack BC Jr, Metter D. Current controversies in the initial post-surgical radioactive iodine therapy for thyroid cancer: a narrative review. Endocr Relat Cancer 2014;21:R473-84. [PMID: 25277792 DOI: 10.1530/ERC-14-0286] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 3.6] [Reference Citation Analysis]
Number Citing Articles
1 Qiao T, Gao D, Tong J, Shen Y, Ma J, Lv Z, Li D. Anxiety and depression status prior to radioactive iodine therapy among differentiated thyroid cancer patients during the COVID‑19 pandemic. Support Care Cancer 2022. [PMID: 36326909 DOI: 10.1007/s00520-022-07422-7] [Reference Citation Analysis]
2 Wang X, Zheng X, Zhu J, Li Z, Wei T. Radioactive iodine therapy may not improve disease-specific survival in follicular variant papillary thyroid cancer without distant metastasis: A propensity score-matched analysis. Head Neck 2021;43:1730-8. [PMID: 33559196 DOI: 10.1002/hed.26637] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Da Silva JG, De Morais RM, Da Silva ICR, Adimy M, De Arruda Mancera PF. A MATHEMATICAL MODEL FOR TREATMENT OF PAPILLARY THYROID CANCER USING THE ALLEE EFFECT. J Biol Syst 2020;28:701-18. [DOI: 10.1142/s0218339020500138] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
4 Ahtiainen V, Vaalavirta L, Tenhunen M, Joensuu H, Mäenpää H. Randomised comparison of 1.1 GBq and 3.7 GBq radioiodine to ablate the thyroid in the treatment of low-risk thyroid cancer: a 13-year follow-up. Acta Oncol 2020;59:1064-71. [PMID: 32603613 DOI: 10.1080/0284186X.2020.1785003] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
5 Vardarli I, Weidemann F, Aboukoura M, Herrmann K, Binse I, Görges R. Longer-term recurrence rate after low versus high dose radioiodine ablation for differentiated thyroid Cancer in low and intermediate risk patients: a meta-analysis. BMC Cancer 2020;20:550. [PMID: 32539683 DOI: 10.1186/s12885-020-07029-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
6 Krčálová E, Horáček J, Gabalec F, Žák P, Doležal J. Scintigraphic evaluation of salivary gland function in thyroid cancer patients after radioiodine remnant ablation. Eur J Oral Sci 2020;128:204-10. [PMID: 32239618 DOI: 10.1111/eos.12689] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
7 Krcalova E, Horacek J, Gabalec F, Zak P, Dolezal J. Salivary gland function in thyroid cancer patients with radioiodine administration history. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2020;164:277-83. [PMID: 31223135 DOI: 10.5507/bp.2019.023] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
8 Özcan Z, Yararbaş Ü. Low-Dose Radioiodine Therapy in Well-Differentiated Thyroid Carcinoma. Thyroid and Parathyroid Diseases 2019. [DOI: 10.1007/978-3-319-78476-2_42] [Reference Citation Analysis]
9 Dehbi HM, Mallick U, Wadsley J, Newbold K, Harmer C, Hackshaw A. Recurrence after low-dose radioiodine ablation and recombinant human thyroid-stimulating hormone for differentiated thyroid cancer (HiLo): long-term results of an open-label, non-inferiority randomised controlled trial. Lancet Diabetes Endocrinol 2019;7:44-51. [PMID: 30501974 DOI: 10.1016/S2213-8587(18)30306-1] [Cited by in Crossref: 45] [Cited by in F6Publishing: 51] [Article Influence: 9.0] [Reference Citation Analysis]
10 Liu H, Wang X, Yang R, Zeng W, Peng D, Li J, Wang H. Recent Development of Nuclear Molecular Imaging in Thyroid Cancer. Biomed Res Int 2018;2018:2149532. [PMID: 29951528 DOI: 10.1155/2018/2149532] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
11 Christakis I, Dimas S, Kafetzis ID, Roukounakis N. Risk stratification of 282 differentiated thyroid cancers found incidentally in 1369 total thyroidectomies according to the 2015 ATA guidelines; implications for management and treatment. Ann R Coll Surg Engl 2018;100:357-65. [PMID: 29484944 DOI: 10.1308/rcsann.2018.0017] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
12 Tumino D, Frasca F, Newbold K. Updates on the Management of Advanced, Metastatic, and Radioiodine Refractory Differentiated Thyroid Cancer. Front Endocrinol (Lausanne) 2017;8:312. [PMID: 29209273 DOI: 10.3389/fendo.2017.00312] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 4.7] [Reference Citation Analysis]
13 Sampathkumar G, Menon AS, M R B, Nair V. Unilateral adrenal mass as the sole initial manifestation of differentiated thyroid cancer. BMJ Case Rep 2017;2017:bcr-2017-221296. [PMID: 28954751 DOI: 10.1136/bcr-2017-221296] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
14 Krčálová E, Horáček J, Kudlej L, Rousková V, Michlová B, Vyhnánková I, Doležal J, Malý J, Žák P. Is radioiodine administration in patients with papillary thyroid multifocal microcarcinoma unnecessary? Endocrinol Diabetes Metab Case Rep 2016;2016:150138. [PMID: 27252861 DOI: 10.1530/EDM-15-0138] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
15 Liou MJ, Tsang NM, Hsueh C, Chao TC, Lin JD. Therapeutic Outcome of Second Primary Malignancies in Patients with Well-Differentiated Thyroid Cancer. Int J Endocrinol 2016;2016:9570171. [PMID: 27118971 DOI: 10.1155/2016/9570171] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
16 Prpic M, Kruljac I, Kust D, Kirigin LS, Jukic T, Dabelic N, Bolanca A, Kusic Z. Re-ablation I-131 activity does not predict treatment success in low- and intermediate-risk patients with differentiated thyroid carcinoma. Endocrine 2016;52:602-8. [PMID: 26732041 DOI: 10.1007/s12020-015-0846-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
17 Lin JD, Hsueh C, Chao TC. Long-Term Follow-Up of the Therapeutic Outcomes for Papillary Thyroid Carcinoma With Distant Metastasis. Medicine (Baltimore) 2015;94:e1063. [PMID: 26131826 DOI: 10.1097/MD.0000000000001063] [Cited by in Crossref: 34] [Cited by in F6Publishing: 39] [Article Influence: 4.3] [Reference Citation Analysis]
18 Pfestroff A, Dietlein M, Luster M. Nuklearmedizinische Diagnostik, Therapie und Nachsorge des Schilddrüsenkarzinoms. Onkologe 2015;21:597-610. [DOI: 10.1007/s00761-014-2859-z] [Reference Citation Analysis]
19 Ain KB. Radioiodine-remnant ablation in low-risk differentiated thyroid cancer: pros. Endocrine 2015;50:61-6. [PMID: 26109472 DOI: 10.1007/s12020-015-0668-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]